Stability Programs

In a data-driven pharmaceutical product quality management system, stability studies are indispensable to justify a material for its intended use after initial release testing. Data generated in stability studies can be used to determine material storage conditions, packaging configurations, shipping conditions, formulation type and compositions, shelf-life for further processing, and end-product shelf-life for patient use. Stability data also inform the degradation mechanism and pathway for a material under certain environmental conditions and therefore, provide a scientific foundation for product quality risk assessment when it is inadvertently exposed to elements deviating from the specified conditions during shipping, handling, or storage. Based on the purpose of the stability studies, they can be classified into the following categories

Stressed stability or forced degradation studies

These studies are designed to purposely degrade drug substance or drug product with various environmental stressors including heat, moisture, light, acid, base, or oxidation. The intensity and duration of a stress condition is so selected that samples are degraded to a moderate extent, e.g. 5% - 20%, to avoid the complication of secondary degradation. Samples under various stress conditions are not only necessary to understand their degradation paths and mechanisms, but also essential to assessing the specificity and stability-indicating property of an analytical method for the analysis of degradation products in the presence of their precursor, the intact parent compound. Guidance for stressed stability studies are available from ICH Q1, and regional health authority such as Brazil Anvisa RDC 964/2025.

Prototype stability studies for formulation development

Stability is a key indicator to the feasibility of a prototype formulation. Limited by the amount of time and resources available, this type of stability studies is designed to reveal the compatibility between a drug substance and a excipient, or quickly identify the vulnerability of a prototype formulation under accelerated conditions defined in a protocol, with contingency samples at long-term storage condition ready to be assessed to confirm the predictability of results at the accelerated condition. Due to the develop nature of such stability studies, they are usually non-GMP, even tested with non-validated but scientifically sound analytical methods. As data generated in prototype studies could later be used to justify a clinical formulation and propose an initial shelf-life for clinical supplies in a regulatory filing, a stability protocol is highly recommended to define and document test duration, frequency, formulation and batch information, sample storage condition, and packaging configuration.

Clinical stability studies

This is a regulatory compliance requirement for demonstrated stability of all clinical trial materials (CTM) throughout their use period. Full GMP stability programs are expected for the initial CTM supply at long-term and accelerated storage conditions to confirm the CTM stability and to build a data set for shelf-life projection. In the case of re-supplying the same CTM, abbreviated stability studies at long-term storage condition can be appropriate to support additional batches of CTM for clinical use. However, if there are any changes in the re-supplied CTM, such as variations in formulation, manufacturing process, packaging, or testing, full GMP stability studies would need to be repeated to assess the impact of the changes to the stability property of the CTM.

Bulk-hold stability studies

To determine the suitability for further processing of in-process drug substance intermediates, drug product intermediates, or bulk drug product beyond 30-day storage, GMP stability data simulating warehouse storage and packaging conditions need to be collected. Duration of such stability studies depends on the desired time coverage and processing need at the manufacturing floor. For bulk-hold stability studies, two separate batches are to be used per ICH Q1F and WHO guidance.

Registration stability studies

This is also called formal or primary stability studies that determine what shelf-life is approvable when a product is seeking regulatory approval. Readers are referred to the detailed guidance in ICH Q1A-Q1F on what lot to be selected, storage conditions, requirements on the test methods, test duration, test frequencies, and stability data evaluation.

In-use stability studies

For a multi-dose finished drug product that needs more than 30-day use period, in-use stability studies simulating patient use is to be carried out with testing at the intermediate time point and at the end, respectively, with enough of the remaining dose in the container against stability acceptance criteria. Testing of two separate batches of finished drug products is preferred per WHO guidance or ICH Q1F with at least one batch approaching the end of the shelf life.

Validation stability studies and post-approval stability studies supporting changes and variations

Three production batches of drug substance and three production batches of drug products in every dose and every packaging configuration, usually from the drug substance process validation and drug product process validation campaigns, respectively, are expected to be set up on stability as a commitment to confirm the proposed retest period for drug substance and the proposed shelf-life for drug products in regulatory filing. Per ICH Q1A guidance, stability duration needs to cover the entire retest period for drug substance under the long-term storage condition, and the proposed shelf-life under the long-term storage condition as well as 6 months of accelerated condition for drug product. In addition, to continue manufacturing production batches without any change, per WHO guidance (ICH Q1F), at least one production batch each year is to be set up on long-term stability unless there is no production batch manufactured in that year.